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For	 rare	 risk	 variants,	 two	 affected	 siblings	 would	 share	 the	 variant	 on	 their	 shared	
identity-by-descent	(IBD)	chromosomes.	We	thus	test	the	distribution	of	rare	variants	on	
IBD	 chromosomes	 and	 non-IBD	 chromosomes.	 TRAFIC	 is	 robust	 to	 population	
stratification	as	 “cases”	and	“controls”	are	matched	within	each	sibpair.	We	show	that	




binary	 trait	 using	 extended	 families.	 Since	 affected	 family	members	 are	more	 likely	 to	
share	risk	variants,	we	propose	to	test	if	rare	variants	are	shared	more	than	expected	given	
the	known	inheritance	vector	and	the	founder	genotypes.	TRAP	is	applicable	from	small	
to	 large	pedigrees	with	multiple	generations,	 including	 families	with	missing	 founders.	








be	 more	 powerful	 than	 the	 existing	 family-based	 methods	 for	 large	 pedigrees;	 for	
ascertained	 scenarios,	 TRACE	 outperforms	 the	 existing	 approaches	 throughout	


















history	 (McCarthy	 et	 al.	 2008;	 Altshuler,	 Daly,	 and	 Lander	 2008).	 Many	 diseases	 are		
measured	 in	 terms	 of	 their	 “heritability”,	 which	 refers	 to	 the	 proportion	 of	 disease	
variance	that	is	attributable	to	the	genetic	contribution	(Manolio	et	al.	2009;	Tenesa	and	
Haley	2013).	Inherited	genetic	variants	are	therefore	presumed	to	play	a	significant	role	







of	susceptible	 loci	and	the	disease	status	 in	families.	Using	 linkage	studies,	researchers	














diseases.	 In	 a	 GWAS,	 a	 sample	 of	 cases	 (i.e.	 people	with	 the	 disease	 of	 interest)	 and	
controls	(people	without	the	disease)	from	a	population	are	genotyped	and	statistically	
tested	to	determine	if	any	variants	are	more	frequently	observed	in	cases	than	controls.	









heritability.	 One	 of	 the	 explanations	 for	 the	 missing	 heritability	 is	 that	 the	 variants	
identified	in	GWAS	are	mostly	common	variants	with	frequency	>	5%	in	the	population	
(Manolio	et	al.	2009).	It	is	believed	that	a	risk	variant	reducing	the	fitness	(causing	a	deadly	












frequency	 <	 0.5%.	 In	 addition,	 sequencing	 protein-coding	 regions	 (~1%	 of	 the	 human	












sample	 size.	 Furthermore,	with	 a	 large	 sample	 size,	 the	 heterogeneity	 in	 samples	 can	
easily	confound	results	and	generate	spurious	signals,	known	as	population	stratification,	
in	 which	 samples	 from	 different	 populations	 consist	 of	 different	 allele	 frequency	 and	
disease	 prevalence	 (Zawistowski	 et	 al.	 2014).	 Methods	 that	 controls	 for	 population	


















the	 existing	methods	 to	 gene-based	 tests,	which	 combine	 the	 information	 across	 rare	








Chen,	Meigs,	 and	Dupuis	 2013;	X.	Wang	et	 al.	 2013).	However,	 the	adjustment	 to	 the	





rare	 variant	 associations	 that	 can	 apply	 to	 both	 binary	 and	 continuous	 traits,	 and	 be	




In	 Chapter	 2,	we	 present	 a	 new	method	 for	 association	 testing	 based	 on	 affected	






stratification	 as	 “cases”	 and	 “controls”	 are	 matched	 within	 each	 sibpair.	 By	 using	
simulations,	we	show	that	TRAFIC	has	the	most	significant	power	gain	over	the	population	
case-control	 design	 for	 rare	 variants	 with	 summed	 allele	 frequency	 <	 5%	 in	 a	 given	
genomic	region.	Considering	allelic	heterogeneity,	where	risk	variants	have	different	effect	
sizes,	 TRAFIC	 doubles	 the	 power	 of	 a	 case-control	 study	 in	 many	 realistic	 parameter	
settings.		
Many	 recent	 family-based	 studies	 collect	 data	 from	 extended	 families	 (Hunt	 et	 al.	
2005;	 Mahmood	 et	 al.	 2014;	 Sidore	 et	 al.	 2015).	 With	 common	 diseases,	 including	




















with	 realistic	 parameter	 configurations	 and	 show	 that,	 given	 the	 same	 number	 of	
sequenced	 individuals,	TRAP	can	substantially	outperform	the	conventional	population	
case-control	design	and	existing	family-based	methods.		
Both	 TRAFIC	 and	 TRAP	 described	 above	 are	 applicable	 to	 test	 for	 rare	 variant	
association	 with	 binary	 traits.	 However,	 continuous	 traits	 are	 routinely	 and	 readily	
collected	in	many	studies;	for	example,	in	a	diabetes	study,	patients	are	often	measured	
for	their	lipid	level,	glucose	level,	waist/height	ratio,	and	blood	pressure.	Existing	family-





increases	the	trait	value,	 this	rare	variant	 is	 likely	to	segregate	 in	 family	members	who	
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have	 a	 high-level	 trait.	 Collecting	 such	 ascertained	 families	 can	 increase	 the	 observed	
frequency	 of	 associated	 variants,	 leading	 to	 power	 gain.	 Although	 powerful,	 the	
ascertainment	 requirement	 typically	 increases	 the	 cost	 of	 collecting	 such	 families,	
resulting	in	a	smaller	sample	size	(given	a	fixed	budget),	which	can	offset	the	increased	
copies	 of	 associated	 variants.	 The	 second	 design	 is	 to	 collect	 a	 larger	 sample	 of	
unascertained	families,	 i.e.	randomly	selected	families	in	a	population.	This	design	may	
still	allow	us	to	observe	excessive	copies	of	risk	variants	within	a	family,	described	as	the	












simulations,	 we	 show	 that	 including	 between-family	 information	 can	 substantially	







test	 for	 rare	 variant	 associations	 with	 complex	 diseases	 by	 using	 family	 samples.	 Our	
methods	provide	practical	sampling	guidelines	for	future	large-scaled	family	studies	which	
can	achieve	the	highest	power	to	detect	associations.	Identifying	associated	rare	variants	











variants	 underlying	 rare	 Mendelian	 diseases	 using	 next-generation	 sequencing	
technology	(Ng	et	al.	2009;	Ng	et	al.	2010).	However,	the	conventional	case-control	design	





>10,000	 individuals	 to	 identify	 the	 signal	 from	 rare	 variants	 (Nelson	 et	 al.	 2012);	
sequencing	 such	 large	 samples	 is	 still	 very	 expensive.	 Moreover,	 large	 samples	 are	







variants,	 it	 is	 unclear	 whether	 such	 methods	 are	 appropriate	 for	 rare	 variant	 tests	
(Mathieson	and	McVean	2012;	Liu,	Nicolae,	and	Chen	2013).		




increased	 by	 collecting	 cases	with	 affected	 relatives	 (Fingerlin,	 Boehnke,	 and	Abecasis	






family	 data.	 Guo	 and	 Shugart	 (2012)	 and	 De	 et	 al.	 (2013),	 extended	 the	 family-based	










Here,	we	propose	a	powerful	 framework	 for	 testing	 rare	variant	associations	using	
affected	 sibpairs.	We	 create	 a	 matched	 design	 by	 comparing	 the	 allele	 count	 of	 rare	
variants	on	shared	identical	by	descent	(IBD)	chromosome	regions	to	the	allele	count	on	
non-shared	identity	by	descent	chromosome	regions	across	affected	sibpairs	in	a	region	
of	 interest.	 Sharing	 status	 of	 chromosome	 regions	 can	 be	 easily	 estimated	 using	 high	
density	genotype	data	 (Keith	et	al.	2008),	and	sharing	status	of	alleles	can	be	 inferred	
conditional	 on	 the	 known	 chromosome	 region	 sharing	 status.	 Intuitively,	 we	 consider	
shared	chromosome	regions	as	“case”	chromosome	regions	and	non-shared	chromosome	
regions	as	“control”	chromosome	regions.	Under	the	null	hypothesis	of	no	association,	
the	 probability	 of	 a	 shared	 chromosome	 region	 carrying	 an	 allele	 is	 identical	 to	 the	
probability	of	a	non-shared	chromosome	region	carrying	an	allele.	Under	the	alternative	
that	 an	 allele	 increases/decreases	 the	 disease	 risk,	 the	 probability	 of	 a	 shared	




the	 summed	 allele	 frequency	 of	 all	 rare	 risk	 variants	 in	 the	 gene	 and	 the	 mean	 and	
variance	 of	 their	 effect	 size	 (Zöllner	 2012).	We	 show	 that	 given	 the	 same	 number	 of	
sequenced	 individuals,	 the	power	of	the	proposed	affected	sibpair	test	 for	rare-variant	
association	with	 family-based	 internal	control	 (TRAFIC)	 is	higher	 than	 the	conventional	














the	 count	 of	 alleles	 of	 rare	 variants	 on	 chromosome	 regions	 shared	 IBD	 between	 the	
siblings	to	the	count	of	alleles	of	rare	variants	on	chromosome	regions	not	shared	 IBD	




hypothesis	under	no	association	is	𝐻5: 𝑝./0 = 𝑝123./0.	Variants	that	are	associated	with	
the	phenotype	(protective	or	causative)	would	differ	in	frequency	between	IBD	and	non-
IBD	 chromosome	 regions.	 Hence,	 we	 can	 test	 for	 departure	 from	 the	 null	 hypothesis	
either	in	a	collapsing	framework	by	considering	the	alternative	𝐻7:	𝑝./0 ≠ 𝑝123./0	or	in	


















































regions	 and	 the	 expected	 allele	 count	 on	 non-shared	 IBD	 chromosome	 regions.	 To	
calculate	these	expectations,	we	assume	that	all	rare	variants	evaluated	in	a	locus	occur	
on	 different	 haplotypes.	 Let	 f	 be	 the	 sum	 of	 population	 allele	 frequencies	 of	 all	 risk	
variants	(summed	risk	allele	frequency).	For	each	sibpair,	we	count	the	number	of	alleles	
H; ∈ {0,1,2}		on	 the	 shared	 chromosome	 regions 		and	 the	 number	 of	 alleles	H1; ∈
{0,1,2,3,4}		on	 non-shared	 chromosome	 regions.	 Let	AAB 		be	 an	 affected	 sibpair	 and	
P H;, H1; AAB, S 	be	the	probability	of	H;, H1;	conditional	on	the	number	of	shared	IBD	
chromosome	 regions	 S ∈ {0,1,2}	.	 Using	 Bayes’	 rule,	 we	 can	 write	 this	 conditional	
probability	as	




where	P AAB H;, H1; 	depends	 on	 the	 underlying	 genetic	 and	 effect	 size	model	 (see	
Appendix	A.3	for	derivations).	Based	on	previous	work	(Zöllner	2012),	we	model	the	effect	
size	(relative	risk)	of	each	risk	haplotype	as	a	random	variable	with	the	first	two	moments	
𝜇	and	σH.	Then,	P H;, H1; AAB, S 	is	fully	determined	by	the	parameters	𝜇,	σH,	and	f.	We	
calculate	 the	power	 for	TRAFIC	based	on	P H;, H1; AAB, S 	for	a	 range	of	 relative	 risk	
parameter	𝜇	and	σH,	and	under	different	𝑓	assuming	a	simple	collapsing	method	(B.	Li	and	
Leal	2008)	to	test	the	association	between	rare	variants	and	the	dichotomous	phenotype	
(more	details	 in	Appendix	A.4).	 To	maintain	 an	overall	 false	positive	 rate	of	 0.05	 after	
testing	20,000	genes	in	the	genome,	we	set	the	false	positive	rate	to	2.5×10-6.	We	compare	











descendants,	 each	 randomly	 inheriting	 one	 chromosome	 region	 from	 each	 parent.	
Following	Risch	(1990),	we	define	the	contribution	to	prevalence	K	at	the	locus	of	interest	








Here	𝐾K𝐾KB 	depends	on	P AAB H;, H1; 	(more	details	in	Appendix	A.3).	The	relative	
risk	 of	 the	 risk	 allele	 follows	 a	 gamma	distribution	with	 specified	𝜇	 and	𝜎H	.	 Thus,	 the	
probability	of	having	both	siblings	in	the	family	affected	is	𝐾K𝐾KB𝐾L𝐾LB 	and	is	set	to	1	if	
the	simulated	probability	exceeds	1.	We	generate	datasets	of	1000	affected	sibpairs	 in	











sibpairs	 between	 the	 two	 populations	 is	 then	 𝜋H	.	 Assuming	 that	 both	 populations	
contribute	 equally,	 we	 generate	 case-control	 samples	 by	 sampling	 1000	 cases,	 a	
proportion	of	𝜋/(1 + 𝜋)	from	population	1	and	1/(1 + 𝜋)	from	population	2.	We	also	
sample	 1000	 controls	 with	 equal	 contribution	 from	 each	 population.	 To	 generate	 a	
stratified	 sample	 for	 TRAFIC,	 we	 generate	 a	 sample	 of	 1000	 affected	 sibpairs	 with	 a	
proportion	 of	𝜋H/(1 + 𝜋H)		from	 population	 1	 and	 a	 proportion	 of	1/(1 + 𝜋H)		from	
population	2.	We	assume	unknown	sharing	status	for	double-heterozygote	sibpairs	who	
share	 one	 IBD	 chromosome	 region	 and	 impute	 the	 sharing	 status	 through	 multiple	
imputation.	To	generate	cases	for	the	selected	cases	design,	we	sample	affected	sibpairs	
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a	 constant	 power	 for	 the	 conventional	 case-control	 study.	 We	 then	 calculate	




model	 based	 simulator	 COSI	 (Schaffner	 et	 al.	 2005)	 to	 generate	 a	 population	 of	 ten	






population	with	𝑓 = 0.025,	𝜇 = 2.52,	and	𝜎H = 0.62;	 then,	we	generate	1000	affected	
sibpairs	and	apply	TRAFIC	to	that	dataset.		
The	 simulated	 data	 contains	 254,	 509	 and	 237	 sibpairs	 who	 share	 0,	 1,	 and	 2	
chromosome	regions,	respectively;	these	equal	to	983	shared	chromosome	regions	and	
2034	 non-shared	 chromosome	 regions.	 Excluding	 42	 sibpairs	 who	 shared	 one	
chromosome	region	with	ambiguous	double-heterozygote	genotypes,	there	are	51	shared	











gene-based	 test	 by	modeling	 allelic	 heterogeneity	 at	 the	 locus	 of	 interest	 based	 on	 a	
summed	allele	frequency	of	all	risk	variants	f	and	a	distribution	of	effect	sizes	with	mean	
𝜇		and	 variance	𝜎H	.	 For	 comparison,	 we	 also	 evaluated	 the	 conventional	 cases-control	
20	
	












To	 quantify	 the	 enrichment	 of	 risk	 variants	 in	 TRAFIC,	we	 calculated	 the	 expected	
summed	minor	allele	frequency	(sMAF)	of	risk	variants	in	cases	and	controls	of	TRAFIC	for	
a	range	of	genetic	models	(see	Appendix	A.4	for	details).	 	 Initially,	we	modeled	a	 locus	
with	constant	genetic	risk	µ	between	1	and	5	for	all	variants	(𝜎H = 0)	(Figure	2-1)	and	a	
disease	 prevalence	 of	 0.01.	 In	 TRAFIC	 (Figure	 2-1a),	 sMAF	 increased	 rapidly	 in	 cases	
(shared	IBD	chromosome	regions)	and	also	increased	roughly	linearly	with	µ	in	controls	
(non-shared	 IBD	chromosome	regions).	 In	 the	conventional	design	 (Figure	2-1b),	sMAF	
increased	in	cases	almost	linearly	with	relative	risk,	only	slightly	faster	than	the	sMAF	in	
controls	of	TRAFIC.	In	the	selected	cases	design	(Figure	2-1c),	sMAF	in	cases	with	affected	
siblings	 increased	 faster	 than	cases	 in	 the	conventional	 case-control	design	but	 slower	














different	 study	 designs.	We	 show	 sMAF	 as	 a	 function	 of	mean	 relative	 risk	 of	 risk	 variants	 for	 (a)	 TRAFIC,	 (b)	 the	
conventional	case-control	design,	and	(c)	the	selected	cases	design	for	summed	allele	frequencies	(f)	of	0.01,	0.05	and	
0.2	and	fixed	variance	of	relative	risk	𝜎H = 0.		
To	 evaluate	 scenarios	 where	 genetic	 effect	 differs	 between	 risk	 variants,	 we	
considered	a	distribution	of	relative	risks	with	𝜎H > 0	while	maintaining	𝜇 = 1.5	(Figure	
2-2);	for	𝑓 = 0.01,	a	value	𝜎H = 0.1	represents	e.g.	a	scenario	of	20	tested	variants	with	
equal	frequencies	where	6	of	the	tested	variants	are	non-functional	(relative	risk	=	1)	and	
14	of	the	tested	variants	have	a	relative	risk	of	1.71.	A	value	𝜎H = 0.2	would	e.g.	represent	




























9	non-functional	 variants	 and	11	 variants	with	 relative	 risk	 1.91.	 Increasing	𝜎H	did	not	
affect	sMAF	in	cases	or	controls	in	the	conventional	design,	as	in	this	design	sMAFs	only	
depended	on	𝜇	(Figure	2-2b).	In	TRAFIC,	sMAF	in	cases	increased	with	σH	while	the	sMAF	
in	 controls	 remained	 constant.	 Similarly,	 in	 the	 selected	 cases	 design,	 sMAF	 in	 cases	
increased	with	σH	,	 albeit	more	 slowly	 than	 for	 TRAFIC	 (Figure	2-2a	 and	 c).	 Even	 if	 the	
average	effect	of	 risk	 variants	 is	1	 (𝜇 = 1	),	 the	difference	 in	 sMAF	between	cases	and	








Based	on	 the	differences	 in	expected	sMAF,	we	calculated	 the	analytical	power	 for	


























Variance of Relative Risk
b.










TRAFIC	had	substantially	higher	power	 than	 the	conventional	design	across	all	 relative	
risks	 analyzed.	 For	 example,	 for	𝑓 = 0.01	and	𝜇 = 2.5	,	 the	 power	 of	 the	 conventional	








on	𝑓	(Figure	2-3b).	For	𝑓 = 0.01	and	0.05	at	𝜇 = 1.5,	the	power	of	TRAFIC	was	uniformly	
greater	 than	 the	 power	 of	 the	 conventional	 design.	 For	𝑓 = 0.2	,	 TRAFIC	 was	 more	
powerful	than	the	conventional	design	for	𝜎H > 0.1.	Even	for	high-prevalence	diseases,	















We	 modeled	 the	 level	 of	 population	 stratification	 by	 the	 parameter	 𝜋		which	
represents	 the	 ratio	 of	 prevalence	 between	 two	 populations	 (see	 methods).	 In	 the	
absence	of	true	risk	variants	(𝜇 = 1, 𝜎H = 0),	the	conventional	case-control	design	and	
the	selected	cases	design	only	achieved	the	nominal	false	positive	rate	at	𝜋 = 1	where	
equal	proportion	of	 cases	 and	 controls	were	 sampled	 from	 the	 two	populations.	Both	



























































































































































































Variance of Relative Risk
























































linkage	 signal	 in	 only	 one	 of	 the	 populations,	 we	 observed	 a	 slightly	 increased	 false	
positive	rate	in	TRAFIC	(Appendix	A.6).	
	
Figure	 2-4.	 False	 positive	 rate	 in	 the	 presence	 for	 population	 stratification	 for	 TRAFIC,	 selected	 cases	 and	 the	
conventional	case-control	design.	The	false	positive	rate	is	shown	as	a	function	of	the	prevalence	ratio	𝜋	between	two	



































marginal	 effect	 at	 the	 “remaining	 genome”	 locus	 to	 maintain	 SRR	 at	 2,	 4	 and	 8.	We	
considered	a	locus	of	 interest	with	f	=	0.01	and	set	the	marginal	relative	risk	to	2.2	for	
models	 with	 no	 interaction	 (𝛾 = 1	)	 or	 synergistic	 interaction	 (𝛾 > 1	),	 and	 to	 2.8	 for	





The	 power	 of	 TRAFIC	 increased	 with	 𝛾		regardless	 of	 SRR	 across	 most	 interaction	








<	 0.38,	 0.31	 and	 0.26	 for	 SRR=2,	 4,	 and	 8,	 respectively.	 For	 this	 extreme	 model	 of	
antagonistic	interaction,	a	variant	that	was	causal	in	a	population	sample	had	a	protective	
effect	 in	 a	 family	 sample.	 Hence,	 the	 minor	 allele	 frequency	 on	 shared	 chromosome	



























































shared	 chromosome	 regions	 as	 new	 “controls”	 can	be	 applied	 to	 any	published	 gene-
based	tests.	In	this	study,	we	evaluated	the	design	for	a	collapsing	gene-based	test	as	the	
power	of	this	test	can	be	calculated	without	specifying	minor	allele	frequency	or	effect	
size	 distribution	 of	 each	 risk	 variant,	 and	 it	 is	 therefore	 easier	 to	 obtain	 general	
conclusions.	However,	TRAFIC	can	also	be	applied	to	dispersion	tests	such	as	SKAT	(Wu	et	








the	 conventional	 case-control	 design	 contained	 more	 independent	 observations.	 This	
power	 gain	 has	 two	 drivers.	 First,	 families	 ascertained	 to	 carry	 multiple	 affected	
individuals	 are	 more	 likely	 to	 segregate	 risk	 variants	 than	 random	 cases	 (Fingerlin,	

























no	evidence	 for	 linkage	 (Appendix	A.6).	However,	 this	 unlikely	 scenario	only	 results	 in	
minor	 increase	of	the	false	positive	rate	and	has	thus	 little	 impact	on	the	utility	of	our	
method.	 As	 the	 efficacy	 of	 current	methods	 to	 control	 for	 population	 stratification	 in	
population	based	designs	for	rare	variant	tests	is	not	clear	(Mathieson	and	McVean	2012;	
Liu,	Nicolae,	and	Chen	2013),	family	based	designs	may	be	necessary	to	avoid	spurious	









In	 conclusion,	 we	 have	 proposed	 TRAFIC	 using	 affected	 sibpairs	 for	 testing	 the	














genetic	 contribution	 (Manolio	 et	 al.	 2009;	 Eichler	 et	 al.	 2010).	 Importantly,	 these	 rare	
variants	are	abundant	in	human	populations.	In	a	sequencing	study	of	202	drug-targeted	
genes	 from	14,002	 individuals,	more	than	95%	of	single-nucleotide	variants	 found	had	
minor	allele	frequency	(MAF)	<	0.5%	(Nelson	et	al.	2012).	In	addition,	rare	variants	can	
make	important	contributions	to	complex	disease	risk.	In	a	recent	sequencing	study	of	63	
known	 prostate	 cancer	 risk	 regions,	 variants	 with	 minor	 allele	 frequency	 0.1-1%	
accounted	for	42%	of	genetic	risk	(Mancuso	et	al.	2016).		




variants	 and	 complex	 diseases,	 conventional	 case-control	 studies	 require	 huge	 sample	
sizes	 (>10,000	 individuals)	 to	have	adequate	power	 (Manolio	et	al.	2009;	Nelson	et	al.	
2012).	 In	 contrast,	 family	 samples	 can	 provide	 power	 gain	 for	 association	 studies,	
especially	 for	 rare	 variants	 (Feng	 et	 al.	 2015).	 When	 combined	 with	 ascertainment	
strategies,	family-based	methods	further	benefit	from	the	enrichment	of	rare	variants.	For	
example,	 collecting	 cases	with	ascertained	 siblings	 and	 comparing	 them	 to	population	
controls	can	significantly	increase	the	power	relative	to	a	population	case-control	design	
(Zöllner	2012).		
Another	 advantage	 of	 family	 studies	 arises	 in	 the	 context	 of	 population	 structure,	
which	is	a	common	confounder	in	association	studies	(Price	et	al.	2006;	Zawistowski	et	al.	
2014).	Rare	variants	are	often	population-specific	or	shared	by	closely	related	populations	




common	 variants	 in	 population	 samples,	 it	 is	 not	 evident	 that	 these	methods	 are	 as	
effective	when	applied	to	rare	variants	 (Y.	Zhang,	Shen,	and	Pan	2013).	Family	data,	 in	

















so	 that	 family-based	 approaches	 often	 appear	 to	 have	 inferior	 power	 compared	 to	
similarly-sized	 population	 case-control	 studies.	 An	 alternative	 approach	 to	 account	 for	
relatedness	 is	to	use	methods	that	only	rely	on	within-family	 information	such	as	FBAT	
(Rakovski	et	al.	2007);	De	et	al.	(2013)	and	Ionia	et.al.	(2013)	extended	FBAT	to	gene-based	
tests.	This	class	of	within-family	approach	often	requires	separating	a	 large	 family	 into	
many	 parent-offspring	 trios,	 leading	 to	 power	 loss	 (Laird	 and	 Lange	 2006).	 In	 general,	




are	 more	 likely	 to	 reside	 on	 chromosomes	 shared	 identity-by-descent	 (IBD)	 among	
affected	 family	 members.	 Hence,	 comparing	 the	 distribution	 of	 rare	 variants	 in	 IBD	
chromosomes	and	non-IBD	chromosomes	in	affected	sibpairs	can	be	more	powerful	than	






from	 founders	 to	 affected	 offspring	 thus	 creating	 a	 departure	 from	 the	 Mendelian	
segregation	 (Figure	 3-1).	 TRAP	 is	 applicable	 to	 any	 type	 of	 pedigree	 structures,	 from	
sibpairs	to	multi-generation	families.	We	evaluate	this	approach	using	simulations	with	
realistic	parameter	configurations	and	show	that,	given	the	same	number	of	sequenced	
















all	 putative	 risk	 variants	 in	 a	 region	 of	 interest	 (e.g.	 a	 gene)	 for	 associations	with	 the	
disease	phenotype.	To	account	for	co-segregating	rare	variants	in	a	region,	we	define	a	
carrier	 chromosome	 as	 a	 region	 carrying	 at	 least	 one	 putative	 risk	 variant.	 If	 any	 rare	
variant	is	associated	with	the	disease,	we	expect	affected	family	members	to	share	carrier	
chromosomes	more	 than	 expected	 at	 random.	 Analogously,	we	 expect	 a	 depletion	 of	
carrier	 chromosomes	 among	 unaffected	 family	members.	 To	 test	 for	 this	 pattern,	 we	
define	𝑋rs ∈ {0,1,2}		as	 the	 number	 of	 carrier	 chromosomes	 for	 the	 jth	 member	 in	 ith	
family.	We	evaluate	the	distribution	of	carrier	chromosomes	in	each	family	by	calculating	








equally	 likely	 to	 be	 a	 carrier	 chromosome.	 Under	 alternative	 that	 a	 variant	 increases	
disease	 risk,	 carrier	 chromosomes	are	more	 likely	 to	be	 shared	among	affected	 family	
members	and	to	be	transmitted	through	paths	that	include	multiple	affected	individuals.	
Conditional	on	the	inheritance	vector	in	family	i,	we	can	thus	generate	the	null	distribution	











xyl 		 where	 𝑛{ 		is	 the	
number	 of	 paths	 and	 	𝑇r
(x)		is	 the	 count	 of	 affected	 individuals	 inheriting	 a	 carrier	

























can	 calculate	 𝜇r =
l
|
1 + 3 + 0 + 0 = 1	 	and	 𝜎rH =
l
|






TRAP	 depends	 on	 information	 from	 founders	 to	 perform	 the	 association	 test.	 In	
practice,	 this	 information	may	be	missing,	especially	 for	 larger	pedigrees	or	 late	onset	
diseases.	 Here,	we	 devise	 an	 algorithm	 to	 impute	 founder	 genotypes	 and	 inheritance	
vector.	There	are	two	steps	in	the	algorithm.	The	first	step	is	to	impute	inheritance	vectors	
and	 the	 phasing	 of	 variants.	 Given	 the	 number	 of	 IBD	 chromosomes	 shared	 between	
family	members,	we	determine	 an	 inheritance	 vector	 for	 each	 family.	 Then,	 given	 the	






𝑝{7r 		and	 thus	 impute	 the	 number	 of	 carrier	 chromosomes	 in	 missing	 founders.	
𝑝{7r 	is	 estimated	 based	 on	 all	 observed	 transmitted	 founder	 chromosomes	 across	
families.	 Alternatively,	 𝑝{7r 	can	 be	 obtained	 from	 existing	 population	 variant	
databases,	e.g.	1000	Genomes	Project	which	contains	 the	majority	 (>	95%)	of	variants	
with	allele	frequency	>	0.5%	(The	1000	Genomes	Project	Consortium	2015).	Specifically,	
for	 a	 family	 with	𝑛r


















samples.	Here	we	define	𝑝	as	 the	disease	 risk,	𝐺 = 𝑔l	, 𝑔H	, … , 𝑔X	|𝑔r ∈ (0,1,2) 	as	 an	
indicator	vector	for	carrying	the	variant	allele	at	mth	variant	of	interest	in	the	region.	For	











= 𝛽5 + 𝛽l𝐺rs + 𝐹rs +
𝜀rs.	Here,	ij	denote	the	jth	individual	in	the	ith	family,	and	𝐹rs~𝑁(0, 𝜎H = 0.5)	is	the	shared	
polygenic	and	environmental	effect	in	a	family.	The	covariance	matrix	in	ith	family	is	𝑽r =







𝐺rs,	 assuming	 no	 recombination	 in	 families,	 we	 sample	 two	 chromosomes	 for	 each	
founder	 from	 those	 ten	 thousand	 chromosomes;	 then,	 each	 offspring	 inherits	 two	
chromosomes	 following	 Mendel	 law	 (MacCluer	 et	 al.	 1986).	 Given	 the	 generated	
chromosomes,	we	simulate	the	phenotype	for	all	family	members	based	on	the	disease	
model	introduced	above	and	only	keep	the	families	that	match	the	specified	number	of	







(Schaid	et	 al.	 2013),	 FB-SKAT	 (Ionita-Laza	et	 al.	 2013),	 and	a	 conventional	 case-control	
design.	Results	that	applied	TRAP	to	all	affected	and	unaffected	family	members	had	a	
negligible	 difference	 in	 power	 compared	 to	 the	 affected-member-only	 analysis	 (Figure	
B-5).	Thus,	 in	 the	 following,	we	consider	TRAP	applied	to	 founders	and	affected	family	
members	only,	leading	to	lower	sequencing	cost.		First,	we	demonstrate	all	methods	are	






























existing	 methods	 for	 population	 samples	 to	 family	 data,	 and	 FB-SKAT	 extended	 the	
framework	of	FBAT	to	gene-based	test.	Both	methods	can	choose	to	perform	gene-based	




those	 results	 in	 burden	 style	 in	 the	 following	 sections.	 We	 considered	 1000	 nuclear	
families	 with	 two	 affected	 and	 two	 unaffected,	 and	 three	 disease	 models	 under	
population	 carrier	 chromosome	 frequency	 f	 of	 0.01,	 0.05	 and	 0.2.	We	 calculated	 the	
power	over	a	range	of	odds	ratios,	r.	Among	the	considered	family-based	tests,	assuming	
disease	prevalence	of	1%,	TRAP	was	uniformly	the	most	powerful	method	from	rare	to	








more	powerful	 than	the	population	case-control	design.	 In	contrast,	 for	higher	disease	
prevalence	 at	 10%,	 none	 of	 the	 family-based	 methods	 showed	 an	 advantage	 in	 any	








Power	 curve	 is	 shown	as	 a	 function	 of	 effect	 size	 r	 (odds	 ratio)	 of	 risk	 variants	 in	 a	 gene	with	 carrier	 chromosome	
frequency	f	=	0.01,	0.05,	0.20.	
3.3.3. Power	 comparison	 with	 additional	 generation	 or	 affected	
members	in	families	
To	evaluate	 the	effect	of	 pedigree	 size	 and	ascertainment	on	TRAP,	we	 considered	















0.01,	given	 three	affected	 family	members	across	pedigree	 structures,	TRAP	with	 two-
generation	pedigree	2g.3a.1u	had	a	similar	power	compared	to	three-generation	pedigree	
3g.3a.4u	 and	 3g.5a.17u.	 For	 instance,	 for	 r	 =	 2.5,	 TRAP	 with	 2g.3a.1u,	 3g.3a.4u,	 and	
3g.5a.17u	had	power	of	0.546,	0.529	and	0.460,	respectively.	Note	that	pedigrees	with	a	
higher	 proportion	 of	 affected	 individuals	 were	 more	 ascertained	 with	 the	 disease;	
therefore,	these	families	were	more	likely	to	carry	risk	variants,	resulting	in	power	gain.	
The	 level	 of	 ascertainment	 can	 be	 quantified	 by	 how	 challenging	 to	 collect	 such	 an	
ascertained	family.	To	collect	a	family	with	2g.3a.1u,	3g.3a.4u,	3g.5a.17u	and	3g.3a.19u	
ascertainment,	the	chance	of	gathering	one	such	family	were	one	in	201,	37,	20	and	5	
equally-sized	 families,	 respectively.	Thus,	3g.3a.17u	was	 the	 least	ascertained	pedigree	
and	thereby	TRAP	had	the	least	power	with.	Although	2g.3a.1u	was	the	most	ascertained	
pedigree	(also	the	most	challenging	to	collect),	it	only	achieved	a	comparable	power	as	
much-less-ascertained	 3g.3a.4u,	 and	 3g.5a.17u,	 suggesting	 a	 pedigree	 with	 three	














two	 founders	 and	 three	 siblings,	 in	 which	 two	 siblings	 were	 affected	 and	 one	 was	
unaffected	 in	order	to	compare	with	Pedgene,	which	 is	not	applicable	to	affected-only	
design.	We	considered	 four	 scenarios	 in	which	all	 founders	were	missing	or	a	 random	
subset	of	founders	were	missing	in	20%,	50%,	and	80%	of	families.	We	compared	TRAP	
imputation	 to	 TRAP	with	 compete	 founder	 information	 (but	 did	 not	 consider	 founder	
phenotypes)	and	to	Pedgene,	which	did	not	require	information	from	founders.	Since	FB-

















we	 evaluated	 the	 degree	 of	 power	 loss	 due	 to	 being	 conservative	 and	 using	 imputed	





were	 two	cases	 for	every	one	control	 in	Pedgene,	and	 this	was	not	optimal	 in	a	 case-







impute	 missing	 founders	 and	 resulted	 in	 only	 minor	 loss	 in	 power.	 This	 approach,	
however,	was	highly	sensitive	to	the	bias	to	the	true	carrier	chromosome	frequency;	even	
a	small	bias	could	lead	to	substantially	inflated	type	I	error	(Figure	B-9).		








In	 sum,	 from	 rare	 to	 common	 variants	 with	 ascertained	 families,	 TRAP	 was	more	
powerful	 than	 the	 two	existing	 family-based	methods	under	many	pedigree	structures	
considered.	Besides,	for	disease	prevalence	1%	and	rare	variants,	TRAP	outperformed	the	
population	 case-control	 design.	 Across	 pedigree	 structures,	 families	 with	 more	
generations	 and	 more	 affected	 family	 members	 increased	 power.	 Importantly,	 we	














among	 affected	 family	 members.	 To	 leverage	 this	 observation,	 TRAP	 compares	 the	
number	of	carrier	chromosomes	in	a	family	to	the	expectation	conditional	on	the	founder	
genotypes	 and	 inheritance	 vectors.	 Equivalently,	 we	 propose	 to	 test	 if	 the	 variant	 is	
equally	likely	to	be	transmitted	through	all	possible	transmission	paths	from	founders	to	







as	 shown	 in	 affected-sibling	 designs	 (Epstein	 et	 al.	 2015;	 Lin	 and	 Zöllner	 2015).	 The	
proposed	method	 TRAP	 not	 only	 better	 exploit	 IBD	 information	 but	 also	 provide	 the	






but	 with	 phenotypic	 information	 available.	 Specifically,	 the	 missing	 genotype	 can	 be	
replaced	by	the	expectation	conditional	on	available	relatives	(W.-M.	Chen	and	Abecasis	
2007).	 Since	 acquiring	 disease	 status	 is	 more	 accessible	 than	 gathering	 genotype	
information,	we	expect	TRAP	 is	especially	useful	when	applying	to	extensive	pedigrees	
with	imputation.		
As	 TRAP	 exploits	 within-family	 information	 and	 includes	 founders	 in	 the	 test,	 it	
achieves	greater	power	compared	to	the	existing	family-based	method	Pedgene,	which	
uses	 both	 between-	 and	 within	 family	 information	 and	 the	 conventional	 case-control	
design.	The	reason	is	that,	 for	a	family	with	multiple	affected	family	members	and	low	
disease	prevalence,	it	is	more	likely	that	founders	carry	the	risk	variant	and	this	influences	




among	 affected	 and	 TRAP	 efficiently	 uses	 the	 inheritance	 vector	 to	 test	 for	 this	
association.	These	two	conditions	significantly	increase	the	power	of	TRAP	to	detect	rare	












was	 only	 advantageous	 to	 identifying	 rare	 variant	 associations	 for	 low	 prevalence	









for	 large-scale	 association	 studies.	 Since	 TRAP	 evaluates	 the	 disproportionate	 sharing	




As	a	 future	 improvement,	we	can	 infer	 founders’	ancestry	and	 their	 individual-specific	
carrier	chromosome	frequency	(Conomos	et	al.	2016),	and	then	accommodate	TRAP	to	
mitigate	the	confounding	effect	of	population	stratification.		





more	prone	 to	 genotyping	error	which	 influences	 the	 accuracy	of	 inferred	 inheritance	
vectors	 than	 nuclear	 families	 (X.	 Li	 and	 Li	 2011).	 As	 the	 size	 of	 pedigree	 grows,	 the	

















































variants	 to	 include	 in	 the	within-family	 association	 test	 to	 reduce	 the	multiple-testing	
burden.	 Fang,	 Sha,	 and	 Zhang	 [2012]	 included	 the	 between-family	 information	 and	
formed	a	combined	test;	a	combined	test	is	more	powerful	than	using	only	within-family	











SKAT,	 which	 is	 a	 gene-based	 test	 extended	 from	 FBAT	 (Ionita-Laza	 et	 al.	 2013)	 and	





new	 efficient	 gene-based	 method	 to	 use	 family	 data	 to	 increase	 power	 for	 the	
identification	of	associated	rare	variants,	focusing	on	continuous	traits.	
To	increase	power	based	on	the	fact	that,	given	a	rare	variant	increases	the	trait,	two	
family	members	who	 have	 a	 high-level	 trait	 are	more	 likely	 to	 share	 this	 rare	 variant	
identity-by-descent	 (IBD).	 Collecting	 ascertained	 families,	 which	 have	 many	 family	
members	who	have	a	high-level	trait,	can	increase	the	observed	frequency	of	risk	alleles,	
leading	to	power	gain.	Although	powerful,	the	ascertainment	requirement	also	increases	













this	 variant	would	pass	 through	 the	 founder	 chromosome	 that	 can	 reach	many	 family	
members	with	high	trait	values	(as	illustrated	in	Figure	4-1).	Therefore,	using	within-family	
information,	 we	 test	 if	 the	 transmission	 path	 is	 associated	 with	 the	 trait	 of	 family	
members.	 Moreover,	 within-	 and	 between-family	 information	 provide	 independent	






is	more	 powerful	 than	 the	 existing	 family-based	methods	 for	 large	 pedigree,	 but	 less	





the	 simulation	model	 that	 accounts	 for	 the	 relatedness	 and	 heritability	 in	 families	 to	











the	number	of	carrier	chromosomes	 for	every	 individual	and	𝑌rs 	be	 the	 trait	value,	𝑖 =
1…𝑛 ¡¢	and	𝑗 = 1…𝑛£.	 In	addition,	we	center	 the	 individual’s	 trait	by	 subtracting	 the	
family	mean	𝑌¤.	To	quantify	the	covariance	between	carrier	chromosomes	and	the	trait,	
we	 calculate	 𝑇r = (𝑌rs − 𝑌¤)
3









the	 trait,	 the	 carrier	 chromosome	 is	 equally	 likely	 to	 be	 transmitted	 through	 any	
transmission	path	 from	 founders	 to	offspring.	Given	 the	 founder	genotypes	𝐿r 	and	 the	
inheritance	 vector	𝐼𝑉r 	,	 we	 can	 thus	 enumerate	 all	 possible	 transmission	 paths	 c	 and	
57	
	








r − 𝐸 𝑇r ],	 aggregates	 the	 information	across	 families.	To	derive	 the	null	
distribution	of	𝑇«,	we	can	rewrite	within-family	information,	𝑇r − 𝐸 𝑇r ,	as	a	summation	
of	the	excessive	transmission	of	carrier	chromosome	and	the	trait	of	each	family	member	
as	below,		
𝑇r − 𝐸 𝑇r = 𝑌rs − 𝑌¤
3
s







= 𝑌rs − 𝑌¤
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s















) = 𝑌rs − 𝑌¤
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where	 	Cov 𝑋rs, 𝑋rs² 𝐿r, 𝐼𝑉r =
µ|wk 𝑋rs 𝐿r, 𝐼𝑉r µ²|wk 𝑋rs² 𝐿r, 𝐼𝑉raw	w|¶,·¸
3w
.	 	Under	













the	 summary	 statistic	 measuring	 the	 covariance	 between	 the	 trait	 and	 carrier	 chromosomes.	 Conditional	 on	 the	
inheritance	 vector	 in	 family	 i,	 we	 can	 thus	 enumerate	 all	 four	 possible	𝑇r
x 	.	 Under	 the	 null	 hypothesis	 that	 each	
placement	 is	 equally	 likely	 to	 occur,	 we	 then	 can	 calculate	𝜇r =
l
|





As	 shown	 in	 equation	 (1),	 within-family	 information	 calculates	 the	 covariance	
between	the	trait	and	carrier	chromosomes	 𝑌rs − 𝑌¤ (𝑋rs − 𝐸 𝑋rs 𝐿r, 𝐼𝑉r .	Define	𝛾r =
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ith	 family.	 Since	 accounting	 for	 the	 expected	 number	 of	 the	 transmitted	 carrier	

















r 	,	 where	𝑓		is	 the	
estimated	 carrier	 chromosome	 frequency	 based	 on	 all	 founders	 and	𝑛r ÎÏÐÑÒÁ		is	 the	




var 𝑇« + var 𝑇/
~𝑁(0,1)	
4.2.3. Simulation	model	
We	 use	 simulations	 to	 compare	 power	 between	 the	 proposed	 tests	 and	 existing	
family-based	 methods.	 We	 consider	 two	 existing	 family	 gene-based	 tests:	 Pedgene	
(Schaid	et	al.	2013),	a	gene-based	test	which	implicitly	uses	both	between-	and	within-
family	information	by	adjusting	for	the	relatedness	in	families,	and	FB-SKAT	that	extends	







Let	 𝑦rs 	 	denote	 the	 trait	 for	 the	 jth	 member	 in	 the	 ith	 family,	 𝐺rs =
𝑔rsl	, 𝑔rsH	, … , 𝑔rsX	|𝑔rs∙ ∈ (0,1,2) 	an	 indicator	 vector	 for	 carrying	 the	 variant	 allele	 at	
mth	 variant	 of	 interest.	 To	 generate	 families,	 we	model	 the	 heritability	 in	 a	 family	 by	
incorporating	the	kinship	matrix	of	ith	family	𝑲r 	and	use	the	trait	model	𝑦rs = 𝛼 + 𝐺rs𝛽 +
𝐹rs + 𝜀rs,	where	𝐹rs 	is	the	corresponding	entry	for	jth	member	in	2𝑲r,	𝛼	is	the	mean,	and	
𝛽 = (𝛽l, 𝛽H, … , 𝛽x)		is	 the	 effect	 size	 of	 the	 risk	 variant	 assuming	 the	 effect	 size	 is	 a	
function	of	minor	allele	 frequency	 (MAF):	𝑟 l
|
logl5(𝑀𝐴𝐹)	;	 thus,	 a	 risk	 variant	of	MAF	
0.0001	has	effect	size	r.	For	neutral	variants,	the	effect	size	is	set	as	zero.	In	this	disease	
model,	the	covariance	matrix	for	ith	family	is	𝑽r = 2𝜎H 𝑲𝒊 + 𝜎H𝑰,	where	𝜎H = 0.5	is	the	






chromosomes	 for	 each	 founder	 from	 those	 ten	 thousand	 chromosomes;	 then	 each	
offspring	 inherits	 two	 chromosomes	 following	Mendel	 law	 (MacCluer	 et	 al.	 1986).	 For	
non-ascertained	scenarios,	we	simulate	the	phenotype	for	all	members	according	to	the	
trait	model	introduced	above	and	keep	every	family	until	a	specified	number	of	families	










































	 2g.4n	 3g.7n.4n	 3g.22n	 2g.2a.2u	 3g.3a.4u	 3g.5a.17u	
TRACE_W	 1.0×10k|	 1.2×10k|	 1.5×10k|	 1.0×10k|	 1.1×10k|	 1.3×10k|	
TRACE	 1.0×10k|	 1.2×10k|	 1.4×10k|	 1.1×10k|	 1.1×10k|	 1.4×10k|	
Pedgene	 1.6×10k|	 1.5×10k|	 1.4×10k|	 1.7×10k|	 1.6×10k|	 1.4×10k|	












the	 maximum	 difference	 in	 power	 between	 TRACE_W	 to	 TRACE	 was	 0.45	 under	 no	












Under	 different	 pedigree	 structures	 and	 ascertainment,	 we	 compared	 TRACE	 to	
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For	 ascertained	 scenarios,	 the	 power	 of	 TRACE	 substantially	 increased	 and	 it	 was	
consistently	 the	 most	 powerful	 method	 from	 small	 to	 large	 pedigree	 settings.	 For	
example,	for	2g.2a.2u	and	effect	size	0.8,	the	power	for	TRACE	and	Pedgene	was	0.64	and	
0.59.	The	advantage	in	power	for	TRAP	was	more	substantial	for	large	pedigree	3g.5a.17u	









In	 this	chapter,	we	developed	a	novel	 family-based	rare-variant	association	 test	 for	




similarity.	 Intuitively,	 if	a	variant	 is	not	associated	with	the	disease,	 it	would	be	equally	
likely	transmitted	to	the	offspring	through	every	founder	chromosome;	thus,	we	evaluate	
if	 the	 variant	 is	 biasedly	 transmitted	 to	 the	 offspring	 through	 a	 specific	 founder	












a	 variant	 that	 increases	 the	 trait	 value,	 leading	 to	 power	 gain.	 In	 addition,	 due	 to	
ascertainment,	it	was	more	likely	that	a	family	segregates	at	least	one	risk	variant,	leading	
to	more	 informative	 families	 in	 the	 test,	 particularly	 for	 large	 pedigrees	with	multiple	
founders;	thus,	we	observe	a	greater	power	gain	for	large	pedigrees	than	small	pedigrees.	
In	general,	Pedgene	reduced	the	effective	sample	size	to	account	for	relatedness	and	did	
not	consider	 the	sharing	of	 rare	variants	 in	a	 family;	 thus,	 the	 larger	 the	pedigree,	 the	
greater	the	power	difference	was	between	TRACE	and	Pedgene.	Although	FB-SKAT	should	
benefit	 from	 ascertainment,	 FB-SKAT	 was	 less	 powerful	 than	 TRACE	 as	 it	 does	 not	
efficiently	 use	 within-family	 information	 and	 breaks	 an	 extended	 family	 into	 trios.	 In	
addition,	FB-SKAT	cannot	consider	parents’	phenotypic	information.		
Under	 non-ascertained	 scenarios,	 TRACE	 includes	 between-family	 information	 and	
substantially	 improves	 power	 over	 TRACE_W,	 especially	 for	 small	 pedigree	 structures.	
Although	Pedgene	reduced	the	effective	sample	size	to	account	for	relatedness,	we	only	
observed	 TRACE	 being	 more	 powerful	 than	 Pedgene	 for	 large	 pedigrees.	 For	 a	 large	
pedigree,	 sharing	 an	 IBD	 variant	 among	 many	 family	 members	 across	 generations	
67	
	
provides	 stronger	 evidence	 that	 the	 variant	was	 associated	with	 disease	 compared	 to	
small	pedigree;	thus,	TRACE	can	better	exploit	within-family	information	to	up-weight	this	
sharing	evidence	as	compared	to	Pedgene	(Appendix	C.2).		
By	 including	 between-family	 information,	 TRACE	 can	 substantially	 increase	 power	
over	 TRACE_W,	 which	 only	 uses	 within-family	 information,	 particularly	 for	 small	
pedigrees.	 We	 note	 that	 including	 between-family	 information	 is	 more	 prone	 to	
population	stratification	due	to	 the	heterogeneity	 in	origin	between	families	 than	only	
using	within-family	information.	However,	TRACE	can	easily	adapt	the	existing	strategy	to	
overcome	 the	common	confounders	 in	association	 studies.	 For	example,	by	 taking	 the	
residual	of	the	trait	adjusted	for	principal	components	and	available	covariates	as	the	new	
trait,	 TRACE	 can	 adapt	 this	 existing	 strategy	 to	 reduce	 false	 positive	 signals	 due	 to	
population	stratification.		
In	conclusion,	we	propose	a	new	powerful	approach	to	better	use	family	information	











Rare	 variants	have	been	hypothesized	 to	explain	part	of	 the	missing	heritability	of	
complex	diseases	(Manolio	et	al.	2009).	With	the	innovation	of	sequencing	technology,	
recent	 studies	 have	 routinely	 assessed	 rare	 variants	 using	 next-generation	 sequencing	
technology	(Sidore	et	al.	2015;	Fuchsberger	et	al.	2016;	Fritsche	et	al.	2016).	However,	








it	 is	 expected	 that	 only	 one	 parent	 in	 a	 family	 carries	 the	 variant;	 thus,	 two	 affected	
siblings	share	the	same	variant,	i.e.	the	rare	variant	resides	on	the	IBD	chromosome.	Using	





samples.	 Furthermore,	 as	 shown	 in	 Zawistowski	 et	 al.	 (2014)	 and	 our	 results,	 minor	
population	stratification	can	substantially	 inflate	type	I	error	rate	and	thereby	generate	
spurious	 association	 signals.	 In	 rare	 variant	 association	 studies,	 adjusting	 for	 principal	
components	(Price	et	al.	2006)	may	not	be	sufficient	to	control	for	population	stratification	
(Mathieson	and	McVean	2012;	Liu,	Nicolae,	and	Chen	2013).	An	alternative	way	to	prevent	
population	 stratification	 is	 to	 use	 prudently	 matched	 cases	 and	 controls.	 Intuitively,	
TRAFIC	uses	non-IBD	chromosomes	to	serve	as	cautiously	matched	“controls”	compared	
to	IBD-chromosomes	as	“cases”	in	each	sibpair	to	be	robust	to	population	stratification.	




2010;	Price	et	al.	2010;	 Lee	et	al.	2014),	 for	example,	 to	 incorporate	 the	variants	with	
different	directions	of	effect.	Furthermore,	 this	 translation	 into	a	“case-control”	design	
also	enables	the	inclusion	of	external	population	samples,	generated	by	many	existing	and	
ongoing	sequencing	projects,	to	further	increase	power.	Recently,	by	matching	with	the	
inferred	 ancestry,	 using	 external	 population	 controls	 have	 been	 proposed	 to	 increase	
sample	sizes	(C.	Wang	et	al.	2014;	Bodea	et	al.	2016).	Although	future	evaluations	of	the	
matching	algorithms	 to	 avoid	population	 stratification	 for	 rare	 variant	 associations	 are	
required,	 in	 principle,	 given	 prudently	 matched	 external	 controls,	 TRAFIC	 can	 further	







use	within-family	 information	 through	 inheritance	vectors,	which	 indicate	 transmission	








structures.	 In	addition,	as	 the	sharing	of	 rare	variants	across	generations	 in	a	 family	 is	
strong	evidence	for	associations,	the	power	gain	increases	with	the	size	of	pedigree.	For	a	





2016).	 At	 the	 same	 time,	 it	 has	 been	 shown	 that	 the	 exponential	 growth	 of	 human	
population	and	selection	can	alter	the	genetic	architecture	of	a	trait	in	which	rare	variants,	
such	as	singletons,	account	for	the	majority	of	the	trait	variance	(Uricchio	et	al.	2016).	In	










how	 linkage	studies	use	 IBD	 information,	 specifically	allele-sharing	 linkage	methods.	 In	
principle,	allele-sharing	linkage	methods	evaluate	whether	there	is	an	excessive	number	











mixed	 models	 or	 logistic	 mixed	 models	 are	 popular	 approaches	 to	 account	 for	 the	
relatedness	in	family-based	studies,	and	many	methods	have	been	developed	based	on	















of	 2	 founders	 and	 2	 offspring	 takes	 <0.001	 second;	 in	 contrast,	 the	 time	 to	 infer	
inheritance	 vectors	 for	 two-generation	 pedigree	with	 3	 founders	 and	 4	 offspring,	 and	
three-generation	 pedigree	 of	 7	 founders	 and	 15	 offspring	 are	 0.01	 and	 108	 seconds,	
respectively.	Although	new	methods	have	been	proposed	to	reduce	the	computational	
burden	to	be	linear	with	the	number	of	non-founders	(X.	Li	and	Li	2011;	O’Connell	et	al.	
2014),	 it	 can	 still	 impose	 a	 computational	 burden	 in	 a	 sample	 with	 many	 extended	
families.	 In	 addition,	 the	 inference	 of	 inheritance	 vectors	 for	 large	 pedigrees	 can	 be	
challenging	when	there	are	multiple	missing	founders	across	generations.	To	account	for	
the	missingness,	enumerating	all	possible	inheritance	patterns	among	missing	founders	
in	 several	 generations	 quickly	 becomes	 computationally	 prohibitive.	 Besides,	 the	






















𝑥1;		be	 the	 number	 of	 minor	 alleles	 located	 on	 non-IBD	 chromosome	 regions.	 Then	
𝑥;, 𝑥1;	are	binomially	distributed	with	the	full	likelihood	function,	








ÙÛÚ 1 − 𝑝1; 𝑁𝑁𝑆−𝑥𝑁𝑆.	
Let	𝑘;	be	the	known	total	number	of	shared	alleles	on	IBD=2	sibpairs	(sibpairs	who	
share	two	IBD	chromosome	regions),	and	𝑘1;	be	the	known	total	number	of	non-shared	
alleles	 on	 IBD=0	 and	 single	 allele	 on	 IBD=1	 sibpairs.	 Suppose	 there	 are	 𝑢		double-
heterozygote	IBD=1	sibpairs.	Among	those	sibpairs,	𝑢;	number	of	sibpairs	share	an	allele	


















𝐸 𝑢; 𝑝;	, 𝑝1; = 𝑢
𝑝; 1 − 𝑝1; H
𝑝; 1 − 𝑝1; H + 1 − 𝑝Z 𝑝1;H
	
𝐸 𝑢1; 𝑝;	, 𝑝1; = 𝑢
1 − 𝑝Z 𝑝1;H
𝑝; 1 − 𝑝1; H + 1 − 𝑝Z 𝑝1;H
.	













𝑝; 1 − 𝑝1; H






















ryl 𝑇r − 𝑇0 H0ryl 	
5. Use	𝑇0	and	𝜎0H	to	perform	the	hypothesis.	
A.2. Simulation	 result	 for	 Imputing	 Double	
Heterozygotes	
We	evaluated	multiple	 imputation	assuming	one	single	underlying	risk	variant	with	






were	the	results	of	shared	alleles	 (naive	estimate),	and	 (3)	using	 the	multiple	 imputed	
sharing	status	(corrected	estimate).	We	set	the	false	positive	rate	at	0.05.	The	test	was	
well	calibrated	if	sharing	status	was	known.	After	applying	multiple	imputation,	there	was	
no	 inflation	 on	 the	 false	 positive	 rate.	 For	 example,	 under	 the	 null	 hypothesis	 of	µ =
1	and	σH = 0,	for	a	single	rare	variant	(f	=	0.01),	the	false	positive	rate	for	the	true,	naïve	










	 True	 Naive	 Corrected	 	 True	 Naive	 Corrected	
f=0.01	 	 	 	 f=0.1	 	 	 	
𝛍 = 𝟏	 0.058	 0.058	 0.055	 𝛍 = 𝟏	 0.054	 0.121	 0.060	
𝛍 = 𝟏. 𝟓	 0.294	 0.313	 0.296	 𝛍 = 𝟏. 𝟐	 0.356	 0.691	 0.324	
𝛍 = 𝟐	 0.835	 0.847	 0.815	 𝛍 = 𝟏. 𝟒	 0.888	 0.992	 0.827	
f=0.05	 	 	 	 f=0.2	 	 	 	
𝛍 = 𝟏	 0.047	 0.057	 0.046	 𝛍 = 𝟏	 0.049	 0.545	 0.049	
𝛍 = 𝟏. 𝟑	 0.464	 0.602	 0.433	 𝛍 = 𝟏. 𝟏	 0.205	 0.903	 0.169	
𝛍 = 𝟏. 𝟓	 0.847	 0.929	 0.806	 𝛍 = 𝟏. 𝟐	 0.557	 0.993	 0.467	
Table	 A-1.	 The	 simulated	 false	 positive	 rate	 and	 power	 for	 TRAFIC	 using	 true	model,	 naïve	 estimate	 and	 corrected	
multiple	imputation	under	different	summed	allele	frequencies	f	and	mean	relative	risk	𝜇.	The	true	model	assumes	the	
sharing	status	of	alleles	is	known.	The	naive	estimate	treats	all	ambiguous	variants	as	shared,	and	the	corrected	multiple	
imputation	uses	 EM	 followed	by	multiple	 imputation	 to	perform	 the	hypothesis	 testing.	 	 The	 sample	 size	was	1000	
sibpairs	and	false	positive	rate	was	set	at	0.05.			
A.3. Calculating	𝐏 𝐇𝑺, 𝐇𝑵𝑺 𝐀𝐀𝑹, 𝐒 	
The	power	of	TRAFIC	depends	on	




where	P AAE H;, H1; 		depends	 on	 the	 underlying	 genetic	 and	 the	 effect	 size	 model	
described	 as	 below,	 and	P S 		is	 the	 segregating	 probability:	P S = 0 = 0.25	,	P S =
1 = 0.50	and	P S = 2 = 0.25.	P H;, H1; S 	is	described	at	the	end	of	this	section.	
A.3.1 Genetic	model	
Suppose	the	population	has	the	disease	prevalence	𝐾.	Let	𝐾𝐾B 	denote	the	recurrence	





𝐾L𝐾LB 	.	 Assume	 there	 are	 m	 distinct	 risk	 haplotypes	ℎl …ℎX	.	 Let	𝜔 ℎZ, ℎ[ 		be	 the	
penetrance	component	of	any	genotype	ℎZℎ[.	Under	the	multiplicative	model,	each	locus	
contributes	 independently	 to	 the	 heritability.	 The	 recurrence	 risk	 can	 be	 expressed	 as	
𝐾𝐾B = 𝐾K𝐾KB𝐾L𝐾LB.	The	probability	of	observing	an	affected	sibpair	given	haplotypes	
(ℎr, ℎs), (	ℎx, ℎò)	is	
P AAE ℎr, ℎs, ℎx, ℎò = 𝜔 ℎr, ℎs 𝜔 ℎx, ℎò 𝐾L𝐾LB.	
A.3.2 Effect	size	model	
We	model	the	effect	size	(relative	risk)	𝜔	of	haplotype	as	a	random	variable	following	
a	 distribution	 g(.)	 with	 the	 first	 two	 moments	µ		and	σH		known.	 The	 penetrance	 for	
haplotype	(ℎr, ℎs)	is	 the	 product	 of	 both	 haplotypes’	 effect	 i.e.	𝜔 ℎr, ℎs = 𝜔r𝜔s 	.	 For	
those	haplotypes	with	no	 risk	alleles,	 the	 relative	 risk	 is	 set	 to	1.	Then	we	can	 further	
express	P AAE H;, H1; = 𝜔l𝜔H𝜔ó𝜔|	as	a	function	of	µ	and	σH	by	using	the	underlying	
genetic	and	effect	model.	
A.3.3 Calculating	𝐏 𝐀𝐀𝐑 𝐇𝐒, 𝐇𝐍𝐒 	
When	 considering	 the	 contribution	 from	 the	 non-shared	 chromosome	 regions,	we	
take	the	average	on	the	range	of	all	possible	effect	sizes	 𝜔𝑔 𝜔 𝑑𝜔 = 𝜇.	In	a	sibpair	who	
shared	an	IBD	chromosome	region,	the	IBD	chromosome	region	is	observed	twice.	Thus,	
the	contribution	of	these	chromosome	regions	to	the	overall	penetrance	would	involve	




P AAE H; = ℎZ, H÷ø = ℎ3Z,




= (µH + σH)^c𝜇^ac 	
A.3.4 Calculating	𝐏 𝐇𝐒, 𝐇𝐍𝐒, 𝐒 	
Given	S,	the	frequency	f	of	carrying	at	least	one	allele	(risk	haplotype)	is	identical	on	
the	shared	and	non-shared	chromosome	regions,	
P H; = ℎZ, H÷ø = ℎ3 S = 0 = 𝑓^a 1 − 𝑓 |k^a 	
P H; = ℎZ, H÷ø = ℎ3 S = 1 = 𝑓^c`^ac 1 − 𝑓 ók^ck^ac 	














𝑁 ×𝑝l× 1 − 𝑝l +
𝑁;






regions,	 respectively.	N	 denotes	 the	 sum	 of	 independent	 chromosome	 regions	 which	
equals	𝑁;	+	𝑁1;.	𝑝l	and	𝑝H	are	the	proportions	of	shared	IBD	chromosome	regions	and	
non-shared	IBD	chromosome	regions	carrying	a	risk	haplotype,	respectively.	The	expected	
number	 of	 independent	 chromosome	 regions	 depends	 on	 P S AAE 		which	 can	 be	
derived	 by	 integrating	 out	 H;	 	and	 H1;	 	in	 P H;, H1;, 𝑆 AAE =
80	
	




Suppose	 there	 are	𝑁		pairs	 of	 affected	 siblings,	 the	 expected	 number	 of	 shared	
chromosome	 regions	 𝑁;		(cases)	 is	 𝑁×P S = 1 AAE + 2𝑁×P S = 2 AAE 		and	 the	
expectation	 of	 non-shared	 IBD	 chromosome	 regions	 𝑁1;	 	(controls)	 is	 2𝑁×
P S = 1 AAE	 + 4𝑁×P S = 0 AAE .	 The	 expectations	 of	 total	 number	 of	 shared	 and	
non-shared	chromosome	regions	carrying	a	risk	haplotype	are	𝐸 𝐻; = 𝑁×E H; AAE =
N×[P H; = 1 AAE + 2×P H; = 1 AAE ]	 	and	 𝐸 𝐻1; = 𝑁×[P H1; = 1 AAE +
2P H1; = 2 AAE + 3P H1; = 3 AAE + 4P H1; = 4 AAE ]	 	respectively;	 the	
marginal	probability	of	H;	and	H1;	can	be	derived	by	integrating	out	the	other	variable	in	
P H;, H1; AAE = P H;, H1;, 𝑆 AAE; 	 .	 	 Thus,	 sMAF	 for	 cases	 and	 controls	 is	
𝐸 𝐻; /E[𝑁;]	and	𝐸 𝐻1; /𝐸[𝑁1;],	respectively.	
𝐸 𝐻; /E 𝑁; = 	
ú H; = 1 AAE `H×ú H; = 1 AAE
ú S = 1 AAE `H×ú S = 2 AAE
	 	
where	
P H; = 1 AAE
= 𝜇H 	+ 𝜎H ∗ 1 − 𝑓 + 𝜇𝑓 H ∗ 𝑓 ∗ 0.5 + 𝜇H 	+ 𝜎H ∗ 2𝑓 1 − 𝑓
∗ 0.25	
P H; = 2 AAE = 𝜇H + 𝜎H H ∗ 𝑓H ∗ 0.25	
P S = 1 AAE = 0.5 ∗ 1 + 𝑓 ∗ 𝜇 − 1
H ∗ 1 + 𝑓 ∗ 𝜇H + 𝜎H − 1 	
P S = 2 AAE = 0.25 ∗ 1 + 𝑓 ∗ 𝜇H + 𝜎H − 1
H
	
𝐸 𝐻1; /𝐸[𝑁1;] =
ú H1; = 1 AAE `Hú H1; = 2 AAE `óú H1; = 3 AAE `|ú H1; = 4 AAE





P H1; = 1 AAE
= 𝜇 ∗ 4 ∗ 𝑓 ∗ 1 − 𝑓 ó ∗ 0.25	 +	 	𝜇 ∗ 1 − 𝑓 + 𝜇 ∗ 𝜇H 	+ 𝜎H ∗ 𝑓
∗ 2𝑓 1 − 𝑓 ∗ 0.5 	
P H1; = 2 AAE
= (𝜇H ∗ 6𝑓H ∗ 1 − 𝑓 H ∗ 0.25	 + (𝜇H ∗ (1 − 𝑓) + 𝜇H ∗ (𝜇H + 𝜎H) ∗ 𝑓)
∗ 𝑓H ∗ 0.5)	
P H1; = 3 AAE = 𝜇ó 		∗ 4𝑓ó(1 − 𝑓) ∗ 0.25	
P H1; = 4 AAE = 𝜇| ∗ 𝑓| ∗ 0.25	
P S = 1 AAE	 = 0.5 ∗ 1 + 𝑓 ∗ 𝜇 − 1
H ∗ 1 + 𝑓 ∗ 𝜇H + 𝜎H − 1 	










𝑝l ∗ 𝑁Z + 𝑝H ∗ 𝑁1Z
𝑁Z + 𝑁1Z
, 𝑝l
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0.05,	 respectively.	We	first	derive	P H;, H1; AAE 	then	calculate	the	expectation	of	H;	
and	H1;	given	both	affteced	siblings.	The	penetrance	for	one	individual	given	genotype	
at	 loci	 L	 and	 G	 is	𝑃 𝐴 	𝐿l = 𝑙, 𝐺l = 𝑔 = 𝛽5𝛽Kò𝛽L
b𝛾ò×b		where	𝐿l = ℎX + ℎ3		and	𝐺l =
𝑔Z + 𝑔[	denote	 the	 number	 of	 risk	 alleles	 at	 loci	 L	 and	G,	 respectively.	 Define	𝑣𝑛𝑠l ∈
{0,1,2}	and	𝑣𝑛𝑠H ∈ {0,1,2}	as	 the	number	of	non-shared	allele	on	 the	 first	and	 second	
sibling,	respectively.	Let	𝑣𝑠 ∈ {0,1,2}	be	the	number	of	shared	alleles	between	a	sibpair.	
The	probability	 of	 having	 both	 affected	 siblings	 given	 the	number	 of	 shared	 and	non-
shared	alleles	is		
𝑃 𝐴𝐴 𝑣𝑛𝑠l, 𝑣𝑛𝑠H, 𝑣𝑠









then	the	expectation	of	H; = 𝑣𝑠	and	H1; = 𝑣𝑛𝑠l + 𝑣𝑛𝑠H	are	
E H÷ø AA = (𝑣𝑛𝑠l + 𝑣𝑛𝑠H)𝑃 𝑣𝑛𝑠l, 𝑣𝑛𝑠H, 𝑣𝑠 𝐴𝐴
&Z&3Z%&3ZÆ
	






𝑃 𝑣𝑛𝑠l, 𝑣𝑛𝑠H, 𝑣𝑠 𝐴𝐴 =
𝑃 𝑣𝑛𝑠l, 𝑣𝑛𝑠H, 𝑣𝑠, 𝐴𝐴
𝑃 𝐴𝐴 	
𝑃 𝑣𝑛𝑠l, 𝑣𝑛𝑠H, 𝑣𝑠, 𝐴𝐴 = 𝑃 𝐴𝐴 𝑣𝑛𝑠l, 𝑣𝑛𝑠H, 𝑣𝑠 𝑃 𝑣𝑛𝑠l, 𝑣𝑛𝑠H, 𝑣𝑠 	




To	 calculate	 the	 number	 of	 shared	 and	 non-shared	 chromosome	 regions,	 the	
derivation	 is	 similar	 but	 has	 to	 be	 conditional	 on	 the	 number	 of	 shared	 chromosome	
region	 𝑆		at	 locus	 L.	 Assuming	 no	 linkage	 between	 L	 and	 G,	 we	 integrate	 out	 the	








	𝑃 𝐴𝐴 𝑣𝑛𝑠l, 𝑣𝑛𝑠H, 𝑣𝑠, 𝑆













𝑃 𝐴 𝑃 𝐴 		
where		
𝑃 𝐴 = 𝑃(𝐴|𝐿l, 𝐺l)𝑃(𝐿l, 𝐺l)HLÆ
H











Pr AA 𝐿l, 𝐺l, 𝑆 	





(𝑃 𝑆∗ = 0 𝑃 𝐺H 𝐺l, 𝑆∗ = 0









the	 extent	 of	 how	 linkage	 affects	 TRAFIC’s	 robustness	 to	 population	 stratification,	 we	
perform	 simulations	 with	 different	 levels	 of	 linkage	 signal	 (LOD	 score)	 and	 show	 the	
genomic	control	𝜆	under	the	null	that	the	tested	variant	is	not	associated	with	the	disease.		
Define	 𝜆./0yH = 𝜆)*	 	is	 the	 recurrence	 risk	 for	 a	 sibpair	 who	 share	 2	 IBD	
chromosomes,	 𝜆./0yl = 𝜆+		is	 the	 recurrence	 risk	 for	 a	 sibpair	 who	 share	 1	 IBD	




𝜆)* + 2𝜆+ + 1 		is	 the	 recurrence	 risk	 for	 a	 sibpair.	 Let	
85	
	
𝑧5	,	𝑧l	,	𝑧H		be	 the	 proportion	 of	 sampled	 sibpairs	 who	 share	 0,1,2	 IBD	 chromosome,	
respectively.	The	expected	values	for	𝑧5,	𝑧l,	𝑧H	is,	
𝐸 𝑧5 = 0.25
1
𝜆;
	 , 𝐸 𝑧l = 0.50
𝜆+
𝜆;




Assuming	 N	 sibpairs,	 the	 expected	 number	 of	 sibpairs	 who	 share	 0,	 1,	 and	 2	 IBD	
chromosomes	 are	 𝑛./0- , 𝑛./0Æ 	,	 and	 𝑛./0% 	,	 respectively,	 where	 𝑛./0- = 𝑁×
𝐸 𝑧5 , 	𝑛./0Æ = 𝑁×𝐸 𝑧l 	, 	𝑛./0% = 𝑁×𝐸 𝑧H .	Thus,	the	expected	LOD	score	is,		
𝐿𝑂𝐷 = logl5
𝐿(𝐸 𝑧5 , 𝐸 𝑧l , 𝐸 𝑧H )
𝐿(𝑧5 =
1
4 , 𝑧l =
1




𝐸 𝑧5 3·/0-×𝐸 𝑧l 	3·/0Æ×𝐸 𝑧H 	3·/0%
0.253·/0-×0.50	3·/0Æ×0.25	3·/0% 	
We	simulate	500	sibpairs	from	each	population;	one	population	has	LOD	score	at	the	
specified	 level	 and	 the	 other	 population	 with	 LOD	 =	 0.	 Then,	 we	 apply	 TRAFIC	 and	
calculate	the	Genomic	Control	𝜆.	Genomic	Control	𝜆	grows	with	increasing	LOD	as	shown	




















































different	 study	 designs	 at	 the	 disease	 prevalence	 of	 0.01.	We	 show	 sMAF	 as	 a	 function	 of	 variance	 of	 relative	 risk	



















B.1. Verification	 of	 Lyapunov	 condition	 in	
Lyapunov	central	limit	theorem	






























































1.5	 1.5	 1.5	 3	 3	 3	 4.5	 4.5	 4.5	
Variance	 0.25	 0.75	 1.25	 0.333	 1	 1.667	 0.25	 0.75	 1.25	
Delta=1	 0.125	 0.937
5	
















𝑁Ç7X ∗ 0.00975 ∗ 0.125 + 0.0195 ∗ 0.9375 + 0.00975 ∗ 1.75













→ 0	𝑎𝑠	𝑁Ç7X → ∞	












conditional	 on	 the	 IBD	 status.	 Without	 loss	 of	 generosity,	 the	 unobserved	 founder	
chromosomes	are	 labelled	as	A,	B,	C,	D;	A,	B	are	paternal	 chromosomes	and	C,	D	are	
maternal	 chromosomes.	 	Assume	we	know	 the	 IBD	 sharing	 status	between	 siblings	as	
shown	below.	At	the	beginning,	we	assign	A,	C	to	Sib	1.	Since	Sib	1	and	Sib	2	share	2	IBD	
chromosome	region,	Sib	2	must	also	have	A,	C.	Given	Sib	3	share	one	IBD	chromosome	
region	 with	 Sib	 1	 and	 Sib	 2,	 Sib	 3	 could	 have	 A,	 D	 or	 B,	 C.	 The	 choice	 of	 possible	
chromosomes	 for	Sib	3	 is	 independent	of	 the	 final	 imputation	 result	 since	 in	 this	 step	















Given	 inheritance	vectors,	phasing	of	 variants	are	 straightforward.	When	 there	are	





algorithm,	 in	which	we	 estimate	 the	minor	 allele	 frequencies	 on	 shared	 chromosome	
regions	𝑝;		and	 non-shared	 chromosome	 regions	𝑝1;		at	 a	 single	 SNP	 position.	 Across	
families,	 let	𝑁;	be	 the	 number	 of	 shared	 chromosome	 regions,	 	𝑥;	be	 the	 number	 of	
minor	 alleles	 located	 on	 IBD	 chromosome	 regions,	𝑁1;		be	 the	 number	 of	 non-IBD	
chromosome	 regions,	 and	 𝑥1;		be	 the	 number	 of	 minor	 alleles	 located	 on	 non-IBD	
chromosome	 regions.	 Then	𝑥;, 𝑥1;		are	 binomially	 distributed	 with	 the	 full	 likelihood	
function,	













ÙÛÚ 1 − 𝑝1; 𝑁𝑁𝑆−𝑥𝑁𝑆.	
For	unambiguous	families,	let	𝑘;	be	the	known	total	number	of	shared	alleles	and	𝑘1;	












xÛÚ`HÞÛÚ 1 − 𝑝1; 1ÛÚkxÛÚkH7ÛÚ 	
where	𝑢; = 𝑢;r 	and	𝜇1; = 𝜇1;r 	To	set	up	the	initial	values	for	the	algorithm,	we	
estimate	 the	 allele	 frequency	 on	 IBD	 chromosome	 regions	𝑝;		by	 counting	 the	 total	





𝐸 𝑢; 𝑝;	, 𝑝1;
=
𝑝;(1 − 𝑝Z) 1 − 𝑝1;
𝑝;(1 − 𝑝Z) 1 − 𝑝1; + 𝑝;(1 − 𝑝Z)𝑝1;
+
𝑝;(1 − 𝑝Z)𝑝1;
𝑝;(1 − 𝑝Z) 1 − 𝑝1; + 𝑝;(1 − 𝑝Z)𝑝1;
	
Only	the	second	configuration	contain	one	non-shared	allele,	thus	
𝐸 𝑢1; 𝑝;	, 𝑝1; =
𝑝;(1 − 𝑝Z)𝑝1;
𝑝;(1 − 𝑝Z) 1 − 𝑝1; + 𝑝;(1 − 𝑝Z)𝑝1;
.	
















𝑝;∗ 1 − 𝑝;∗ 1 − 𝑝1;∗
𝑝;∗ 1 − 𝑝;∗ 1 − 𝑝1;∗ + 𝑝;∗ 1 − 𝑝;∗ 𝑝1;∗
,	
𝑝H =
𝑝;∗ 1 − 𝑝;∗ 𝑝1;∗































3. Impute	 the	 number	 of	 carrier	 chromosomes	 in	 missing	 founders.	 For	 example,	
suppose	 for	 family	 i,	 there	are	 	𝑛r
XrZZr3b	missing	 founder	chromosomes,	we	 impute	
the	 number	 of	 carrier	 chromosomes	 𝑥r{7r 	 	based	 on	
𝑥r{7r~𝐵𝑖𝑛𝑜𝑚𝑖𝑎𝑙 𝑛r































B.3. Compare	 three	 combining	 rules	 for	
multiple	imputation	for	TRAP	
Suppose	 I	use	M	rounds	of	multiple	 imputation,	 let	𝑖	be	 the	𝑖[^	family	among	𝑛Ç7X	




























































3. Apply	 TRAP	 then	 combine	 across	multiple	 imputation	 with	 Chi-square	 statistic	
(Test_Combine_Chisq)	
𝑋(ò) = 𝐷H(ò) =













()òyl 𝑋(ò) − 𝑎)H






𝜈) = (𝑀 − 1)(1 + 𝑟)kH)	
𝑡𝑒𝑠𝑡	𝑠𝑡𝑎𝑡𝑖𝑠𝑡𝑖𝑐 =




































































































To	 compare	how	TRAP,	Pedgene,	 FB-SKAT	use	within-family	 information,	 I	 consider	
TRAP	 in	 two	 scenarios:	 first	 look	 at	 each	 trio	 separately,	 equivalent	 to	 using	 FB-SKAT.	
Second,	 I	use	the	regular	TRAP	to	analyze	this	pedigree.	 I	also	compare	to	Pedgene	by	
assuming	 a	 simple	 burden	 test.	 I	 quantify	 the	 overall	 information	 by	 their	 resulting	 Z	
statistics.	
When	separately	evaluating	each	trio,	the	enumerated	summary	statistics	for	each	trio	
based	 on	 TRAP	 (FB-SKAT)	 is	 (0,1,1,0),	 thus	𝜇 = 0.5		and	𝜎H = 0.25	.	 Thus,	 the	 overall	
information	is	(1-0.5+1-0.5)/sqrt(0.25+0.25)=1.414	
When	collectively	looking	at	the	pedigree,	the	enumerated	summary	statistics	for	each	
trio	based	on	TRAP	is	(0,2,1,0,1,0),	thus	𝜇 = 0.67	and	𝜎H = 0.83.	The	overall	information	
is	(2-0.67)/sqrt(0.83)=1.459	
I	evaluated	Pedgene	using	the	following	equation,		























	I	 used	 the	 estimated	 frequency	 	 𝑓	 	based	 on	 founders.	 In	 this	 case,	




information	 is	 the	 most	 informative.	 Under	 non-ascertained	 scenarios,	 between-
information	 is	 useful.	 But,	 for	 large	 pedigree,	 within	 family	 information	 is	 more	
informative	with	a	smaller	number	of	families.	Thus,	within-family	information	out-weight	
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